Is It Time To Reassess Exelixis (EXEL) After Strong Multi-Year Share Price Gains [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Over the short term, Exelixis has posted returns of 5.4% over the last 7 days, 9.5% over the last 30 days, 6.0% year to date and 33.9% over the last year, with a 3 year return of 175.1% and a 5 year return of 89.5%. These moves have been set against a backdrop of ongoing interest in Exelixis as a US based pharmaceuticals and biotech company. Investors are paying close attention to how its drug portfolio and pipeline position it in the sector. That context is important when you think about whether the recent share price levels line up with what the business might be worth. Exelixis currently scores 5 out of 6 on our valuation checks . Next we will look at how different methods such as multiples and discounted cash flow models assess that, before finishing with an even more practical way to think about valuation in your own process. Exelixis delivered 33.9% returns over the last year. See how this stacks up to the rest of the Biotechs industry. The Discounted Cash Flow model es
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 [Yahoo! Finance]Yahoo! Finance
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026Business Wire
- How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans [Yahoo! Finance]Yahoo! Finance
- Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
EXEL
Earnings
- 11/4/25 - Beat
EXEL
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form SCHEDULE
- 12/12/25 - Form 144
- EXEL's page on the SEC website